Article · Wikipedia archive · Last revised Jul 22, 2026

PAL-335

PAL-335 is a selective serotonin releasing agent (SSRA) which has been used in scientific research. It has been found to increase reward responsiveness in rodents similarly to the serotonin–norepinephrine–dopamine releasing agent and entactogen MDMA and the norepinephrine–dopamine releasing agent and stimulant 3-methylamphetamine. The drug has also been found to impair task performance similarly to MDMA but unlike 3-MA. The interoceptive effects of PAL-335 in drug discrimination studies are being assessed. PAL-335 was first described in the scientific literature by Bruce E. Blough and colleagues in 2026. It is being used as a tool to help study the mechanisms underlying the rewarding effects and misuse liability of MDMA. The chemical structure of PAL-335 does not yet appear to have been disclosed.

Last revised
Jul 22, 2026
Read time
≈ 1 min
Length
222 w
Citations
13
Source
Wikipedia ↗
PAL-335
Clinical data
Other namesPAL335
Drug classSelective serotonin releasing agent (SSRA)
ATC code
  • None

PAL-335 is a selective serotonin releasing agent (SSRA) which has been used in scientific research.12 It has been found to increase reward responsiveness (a prohedonic effect) in rodents similarly to the serotonin–norepinephrine–dopamine releasing agent and entactogen MDMA and the norepinephrine–dopamine releasing agent and stimulant 3-methylamphetamine (3-MA; PAL-314).12 The drug has also been found to impair task performance similarly to MDMA but unlike 3-MA.12 The interoceptive effects of PAL-335 in drug discrimination studies are being assessed.12 PAL-335 was first described in the scientific literature by Bruce E. Blough and colleagues in 2026.1 It is being used as a tool to help study the mechanisms underlying the rewarding effects and misuse liability of MDMA.12 The chemical structure of PAL-335 does not yet appear to have been disclosed.12

See also

See also

References

References

  1. Bloom N, LaMalfa KS, Blough BE, Kangas B (2026). "Toward a Comprehensive Profile of MDMA as a Candidate Therapeutic: The Role of the Dopamine-Serotonin Continuum in Prohedonic Efficacy and Abuse Liability (Abstract ID: 228563)". The Journal of Pharmacology and Experimental Therapeutics. 393 (5) 104268. doi:10.1016/j.jpet.2026.104268.
  2. Bloom NB, LaMalfa KS, Blough BE, Kangas BD (2026). Optimizing MDMA: Neurochemical Mechanisms Underlying Prohedonic Efficacy and Abuse Potential (PDF). 2026 Behavior, Biology, and Chemistry (BBC): Translational Research in Substance Use Disorders. p. 19.